Bristol-Myers Squibb Company
Stock Forecast, Prediction & Price Target
Bristol-Myers Squibb Company (BMY) stock Price Target by analysts
$59
Potential upside: 22.05%
Bristol-Myers Squibb Company price prediction
What is Bristol-Myers Squibb Company stock analysts` prediction?
Bristol-Myers Squibb Company stock forecast: Based on 2 Wall Street analysts` predicted price targets for Bristol-Myers Squibb Company in the last 3 months, the avarage price target is $59, with a high forecast of $NaN. The average price target represents a 22.05% change from the last price of $48.34.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
Bristol-Myers Squibb Company stock Price Target by analysts
Full breakdown of analysts given Bristol-Myers Squibb Company price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
Evan Seigerman BMO Capital | 0% 0/4 | 11 months ago | $61 26.18% upside | $56.23 | TheFly | Previous targets (3) |
Evan David Seigerman BMO Capital | 33.33% 1/3 | 11 months ago | $57 17.91% upside | $54.32 | StreetInsider | Previous targets (2) |
Evan David Seigerman BMO Capital | 33.33% 1/3 | about 1 year ago | $48 -0.70% downside | $49.56 | StreetInsider | Previous targets (2) |
Carter Gould Barclays | 50% 1/2 | about 1 year ago | $41 -15.18% downside | $50.45 | TheFly | Previous targets (1) |
Chris Shibutani Goldman Sachs | 0% 0/1 | about 1 year ago | $57 17.91% upside | $50.55 | StreetInsider | Previous targets (0) |
Trung Huynh UBS | 0% 0/1 | about 1 year ago | $43 -11.04% downside | $40.68 | TheFly | Previous targets (0) |
Steve Scala Cowen & Co. | 0% 0/1 | over 1 year ago | $67 38.60% upside | $44.11 | StreetInsider | Previous targets (0) |
James Shin Deutsche Bank | 0% 0/1 | over 1 year ago | $55 13.77% upside | $49.87 | Benzinga | Previous targets (0) |
Evan Seigerman BMO Capital | 0% 0/4 | almost 2 years ago | $60 24.12% upside | $49.76 | Benzinga | Previous targets (3) |
David Risinger Leerink Partners | 0% 0/1 | almost 2 years ago | $66 36.53% upside | $56.25 | Benzinga | Previous targets (0) |
Louise Chen Cantor Fitzgerald | 0% 0/1 | about 2 years ago | $75 55.15% upside | $59.67 | Benzinga | Previous targets (0) |
Mohit Bansal Wells Fargo | 100% 1/1 | over 3 years ago | $70 44.80% upside | $78.22 | Pulse 2.0 | Previous targets (0) |
Unknown Barclays | N/A | over 3 years ago | $68 40.67% upside | $75.27 | Benzinga | N/A |
Seamus Fernandez Guggenheim | 50% 1/2 | over 3 years ago | $80 65.49% upside | $75.27 | TheFly | Previous targets (1) |
Evan Seigerman BMO Capital | 0% 0/4 | over 3 years ago | $87 79.97% upside | $75.08 | TipRanks Contributor | Previous targets (3) |
Unknown BMO Capital | N/A | over 3 years ago | $92 90.31% upside | $75.66 | Benzinga | N/A |
Terence Flynn Morgan Stanley | 100% 1/1 | over 3 years ago | $64 32.39% upside | $76.5 | Pulse 2.0 | Previous targets (0) |
Evan Seigerman BMO Capital | 0% 0/4 | over 3 years ago | $81 67.56% upside | $73.79 | Pulse 2.0 | Previous targets (3) |
Matthew Harrison Morgan Stanley | 100% 1/1 | over 3 years ago | $66 36.53% upside | $73.11 | Pulse 2.0 | Previous targets (0) |
Evan David Seigerman BMO Capital | 33.33% 1/3 | over 3 years ago | $74 53.08% upside | $70.52 | Pulse 2.0 | Previous targets (2) |
Carter Gould Barclays | 50% 1/2 | almost 4 years ago | $66 36.53% upside | $56.22 | StreetInsider | Previous targets (1) |
Andrew Baum Citigroup | 100% 1/1 | almost 4 years ago | $75 55.15% upside | $56.89 | TheFly | Previous targets (0) |
Seamus Fernandez Guggenheim | 50% 1/2 | about 4 years ago | $82 69.63% upside | $59.05 | StreetInsider | Previous targets (1) |
Justin Smith Societe Generale | 0% 0/1 | about 4 years ago | $85 75.83% upside | $63.63 | StreetInsider | Previous targets (0) |
Geoff Meacham Bank of America Securities | 100% 1/1 | about 4 years ago | $78 61.35% upside | $65.88 | TipRanks | Previous targets (0) |
Bristol-Myers Squibb Company Financial Estimates
Bristol-Myers Squibb Company Revenue Estimates
Bristol-Myers Squibb Company EBITDA Estimates
Bristol-Myers Squibb Company Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $46.38B N/A | $46.15B -0.48% | $45.00B -2.49% | Avg: $46.05B Low: $44.96B High: $47.39B avg. 2.33% | Avg: $43.87B Low: $42.52B High: $44.98B avg. -4.73% | Avg: $44.77B Low: $43.40B High: $45.91B avg. 2.05% | Avg: $41.49B Low: $40.22B High: $42.55B avg. -7.32% |
Net Income
% change YoY
| $6.99B N/A | $6.32B -9.53% | $8.02B 26.83% | Avg: $10.22B Low: $5.73B High: $13.90B avg. 27.35% | Avg: $10.15B Low: $5.63B High: $13.83B avg. -0.65% | Avg: $13.65B Low: $13.10B High: $14.10B avg. 34.47% | Avg: $12.75B Low: $12.24B High: $13.17B avg. -6.55% |
EBITDA
% change YoY
| $20.18B N/A | $19.92B -1.28% | $19.36B -2.79% | Avg: $17.44B Low: $17.03B High: $17.95B avg. -9.92% | Avg: $16.61B Low: $16.10B High: $17.03B avg. -4.73% | Avg: $16.95B Low: $16.43B High: $17.38B avg. 2.05% | Avg: $15.71B Low: $15.23B High: $16.11B avg. -7.32% |
EPS
% change YoY
| $3.15 N/A | $2.97 -5.71% | $3.88 30.63% | Avg: $5.29 Low: $2.76 High: $6.69 avg. 36.24% | Avg: $5.41 Low: $2.71 High: $6.66 avg. 2.29% | Avg: $6.57 Low: $6.31 High: $6.79 avg. 21.51% | Avg: $6.14 Low: $5.89 High: $6.34 avg. -6.55% |
Operating Expenses
% change YoY
| $27.90B N/A | $26.91B -3.54% | $34.31B 27.47% | Avg: $8.05B Low: $7.86B High: $8.28B avg. -76.52% | Avg: $7.67B Low: $7.43B High: $7.86B avg. -4.73% | Avg: $7.82B Low: $7.58B High: $8.02B avg. 2.05% | Avg: $7.25B Low: $7.03B High: $7.44B avg. -7.32% |
FAQ
What is Bristol-Myers Squibb Company stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 13.65% in 2025-2028.
We have gathered data from 15 analysts. Their low estimate is 5.73B, average is 10.22B and high is 13.90B.
What is Bristol-Myers Squibb Company stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of -1.91% in 2025-2028.
We have gathered data from 19 analysts. Their low revenue estimate is $44.96B, average is $46.05B and high is $47.39B.
What is Bristol-Myers Squibb Company stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 13.37% in 2025-2028.
We have gathered data from 15 analysts. Their low earnings per share estimate is $2.76, average is $5.29 and high is $6.69.
What is the best performing analyst?
In the last twelve months 2 analysts have been covering Bristol-Myers Squibb Company stock. The most successful analyst is Evan Seigerman.